Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?

Authors

  • Samuel So,

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Carlos Esquivel,

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Joanne Imperial,

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Gabriel Garcia,

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Humberto Monge,

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Emmet Keeffe

    1. Liver Transplantation Program, Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author

Samuel So Liver Transplant Program, Stanford University School of Medicine, 750 Welch Road, Suite 319, Palo Alto, CA 94304, USA. Email: <samso@stanford.edu>

Abstract

To assess whether Asian race is an independent variable affecting survival and hepatitis B virus (HBV) recurrence after liver transplantation, the results of 27 consecutive liver transplants performed between June 1994 and April 1997 for HBV cirrhosis were analysed. In the group of 13 Asians, 38% had associated hepatocellular carcinoma and 62% had positive hepatitis B virus early antigen (HBeAg) or elevated HBV-DNA before transplant. Prophylactic hepatitis B immunoglobulin (HBIG) was administered perioperatively and long term at 4–6 weekly interval. Four patients with elevated HBV-DNA received lamivudine before transplantation. The 3 year actuarial patient survival rate was 100% in both Asian and non-Asian patients. Twenty-six patients remained seronegative for hepatitis B virus surface antigen after transplantation. The incidence of post-transplant HBV recurrence was similar: 0% in Asians compared with 7% in non-Asians. There was no recurrence in the group of 12 patients who were HBV-DNA or HBeAg negative pretransplant.

Ancillary